Analyst Price Target is $38.00
▲ +70.94% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Chinook Therapeutics in the last 3 months. The average price target is $38.00, with a high forecast of $44.00 and a low forecast of $30.00. The average price target represents a 70.94% upside from the last price of $22.23.
Current Consensus is
The current consensus among 9 contributing investment analysts is to buy stock in Chinook Therapeutics. This Buy consensus rating has held steady for over two years.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.